A Randomized, Double Blind, Placebo Controlled Trial on the Effect of Rosiglitazone in Reversion of Newly Diagnosed Type 2 Diabetes to Non-Diabetic Status
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2016
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 Sep 2012 Planned number of patients changed to 80.
- 18 Sep 2012 Additional trial identifier (ChihiCTR-TRC06000683) identified as reported by Chinese Clinical Trial Register.
- 18 Apr 2012 New trial record